TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M

TriSalus Life Sciences, Inc.

2025-FY EPS reported -$1.84 revenue$45,151,000

Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.
Revenue growth exceeded prior guidance of 50% annual growth for 2025.
Initial 2026 revenue guidance set at $60M to $62M.
Year-end cash approx $20.4M, down $2.3M from start of Q4 reflecting investment in growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.